Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00950404 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet
A Phase 1 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00950404 is a Phase 1 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 16 participants.
The verdict
NCT00950404, a Phase 1 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The bioavailability of the oral disintegrating tablet formulations given without water will be similar to an equivalent dose of the standard oral tablet given with water.
Interventions
- DRUG Viagra 50 mg tablet
- DRUG Formulation B ODT tablet 50 mg
- DRUG Formulation C ODT tablet 50 mg
- DRUG Formulation D ODT tablet 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00950404
The ClinicalTrials.gov registry entry for NCT00950404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Viagra 50 mg tablet is the first listed.
NCT00950404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00950404 about?
NCT00950404 is a clinical study titled "Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet". The bioavailability of the oral disintegrating tablet formulations given without water will be similar to an equivalent dose of the standard oral tablet given with water.
What is the current status of trial NCT00950404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00950404?
The interventions under investigation include: Viagra 50 mg tablet (DRUG), Formulation B ODT tablet 50 mg (DRUG), Formulation C ODT tablet 50 mg (DRUG), Formulation D ODT tablet 50 mg (DRUG).
Who is sponsoring clinical trial NCT00950404?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.